Clinical trial · Observational
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population
NCT02363868CI-TRIAL-00018467completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia (CML) | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- CML subjects receiving Dasatinib
- description
- CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs
- label
- CML subjects receiving Nilotinib
- description
- CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs
Primary outcomes (1)
- measure
- Healthcare costs
- timeFrame
- Intent-to-treat (ITT) at 6 months
- description
- Average (mean) costs for patients receiving dasatinib or nilotinib as first line therapy
Secondary outcomes (2)
- measure
- Healthcare costs by line of therapy
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Age \>18 years * International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) code for CML (205.1x) * At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013 * Continuous eligibility for the 6 months pre- and post-index date (defined as the date of first fill for dasatinib or nilotinib) Exclusion Criteria: * History of bone marrow or stem cell transplant as identified in the 6 month pre-period
References
Publications (0)
Data not yet available
No reference posted for this study.